PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.
PACB - Pacific Biosciences of California, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$1.18
DETAILS
HIGH:
$1.35
LOW:
$1.00
MEDIAN:
$1.18
CONSENSUS:
$1.18
DOWNSIDE:
43.41%
Stock News
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Here’s Why
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) shares gapped down before the market opened on Monday. The stock had previously closed at $2.33, but opened at $2.24. Pacific Biosciences of California shares last traded at $2.1750, with a volume of 1,112,425 shares. Wall Street Analysts Forecast Growth Several equities analysts recently issued
Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells $2,058,244.65 in Stock
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) insider James Gibson II sold 661,815 shares of Pacific Biosciences of California stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $3.11, for a total value of $2,058,244.65. Following the completion of the sale, the
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.
3 Biotech Stocks Put Traders Are Targeting Today
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.
Pacific Biosciences of California (NASDAQ:PACB) Stock Sees Heavy Call Option Buying
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors acquired 13,687 call options on the stock. This represents an increase of 795% compared to the average volume of 1,530 call options. Wall Street Analysts Forecast Growth Several analysts have recently weighed in
Pacific Biosciences of California (NASDAQ:PACB) Shares Climb 6.1% – Still a Buy?
Shares of Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) rose 6.1% on Monday. The company traded as high as $1.68 and last traded at $1.7190. 2,798,059 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 6,597,147 shares. The stock had previously closed at $1.62. Wall
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push
Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion.
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.
Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference
MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:50 PM ET in New York, New York.
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity
Pacific Biosciences of California NASDAQ: PACB reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 million in instrument revenue and $6 million in services revenue, CFO Jim Gibson said during the Canaccord Genuity Growth Conference.
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut
PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.
Price Targets
PacBio assumed with a Neutral at UBS
$1.35
(was $1.32)
UBS
PacBio price target lowered to $1 from $1.50 at Barclays
$1.00
(was $1.45)
Barclays
PacBio price target raised to $1.70 from $1.50 at Bernstein
$1.70
(was $1.33)
Eve Burstein
·
Bernstein
PacBio price target lowered to $1.50 from $2 at Barclays
$1.50
(was $1.22)
Luke Sergott
·
Barclays
Jefferies Starts Pacific Biosciences of California (PACB) at Buy
$4.00
(was $1.79)
Tycho Peterson
·
Jefferies
PacBio price target lowered to $4 from $10 at Morgan Stanley
$4.00
(was $1.98)
Tejas Savant
·
Morgan Stanley
PacBio price target lowered to $2 from $6.50 at Piper Sandler
$2.00
(was $1.77)
David Westenberg
·
Piper Sandler
PacBio price target lowered to $2 from $3 at Barclays
$2.00
(was $1.72)
Luke Sergott
·
Barclays
Goldman Sachs Downgrades Pacific Biosciences of California (PACB) to Neutral
$2.50
(was $1.40)
Matthew Sykes
·
Goldman Sachs
PacBio price target lowered to $3.50 from $10 at Canaccord
$3.50
(was $1.40)
Kyle Mikson
·
Canaccord Genuity
Canaccord Genuity Maintains Buy on Pacific Biosciences, Raises Price Target to $14
$14.00
(was $10.80)
Canaccord Genuity
Pacific Biosciences price target raised to $7.50 from $6 at Piper Sandler
$7.50
(was $7.61)
David Westenberg
·
Piper Sandler
Pacific Biosciences price target lowered to $6 from $13 at Piper Sandler
$6.00
(was $5.84)
David Westenberg
·
Piper Sandler
PacBio Stock (PACB): $20 Price Target From Piper Sandler
$20.00
(was $14.45)
David Westenberg
·
Piper Sandler